Ultimovacs ASA: Notice of convening the extraordinary general meeting of January 9, 2024 – CORRECTION

Oslo, December 19, 2024: Reference is made to the stock exchange notice published by Ultimovacs ASA (the “Company”) on December 17, 2024 regarding the proposed business combination between the Company and Zelluna Immunotherapy AS and the private placement entirely engaged and on the stock market. notice published today at 07:00 CET. Today’s notice was missing an attachment. All documents are included in this announcement,

The board of directors of the Company (the “Board”) hereby convenes an extraordinary general meeting on January 9, 2025 at 09:00 CET (the “EGM”) to decide on the matters proposed by the Board in the notice of notice of the AGM attached.

The EGM will be held electronically. To participate, please log in with the username and password provided.

All documents and annexes relating to the EGM are available on the Company’s website: www.ultimovacs.com.

For more information, please visit www.ultimovacs.com or contact:

Hans Vassgård Eid, Acting CEO and CFO, Ultimovacs ASA
Email: [email protected]
Telephone: +47 482 48632